Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14837874 | 1.00 | KDM4E (0.35) | KDM4EMAPTPIM1PIM2BCHE | |
| SCHEMBL14958112 | 0.77 | MAPT (0.47) | KDM4EMAPTBCHECA12 | |
| SCHEMBL14958113 | 0.77 | MAPT (0.47) | KDM4EMAPTBCHECA12 | |
| SCHEMBL14835744 | 0.77 | PIM1 (0.43) | PIM1PIM2PTPN1CA2SCN9A | |
| SCHEMBL16510130 | 0.77 | PIM1 (0.40) | KDM4EMAPTPIM1PIM2PTPN1 | |
| SCHEMBL14835407 | 0.73 | BCHE (0.38) | BCHE | |
| SCHEMBL14834911 | 0.71 | KDM4E (0.52) | KDM4EMAPTCA12 | |
| SCHEMBL14834915 | 0.71 | KDM4E (0.52) | KDM4EMAPTCA12 | |
| SCHEMBL10030738 | 0.70 | L3MBTL1 (0.41) | KDM4EMAPTPTPN1SCN9A | |
| SCHEMBL16955079 | 0.69 | GSK3A (0.36) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2576514-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT SA (FR) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB, TUBB1 | KDM4E 3218/4885MAPT 29/4885PIM1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.